Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May 10, 2017, Array BioPharma Inc. issued a press release
reporting results for the third quarter of fiscal year ending
June 30, 2017, the full text of which is attached hereto as
Exhibit 99.1. The information in Item 2.02 of this Form 8-K and
the exhibit attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits
| ExhibitNo. | Description | |
| 99.1 |
Press release dated May 10, 2017 entitled Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2017 |
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382. Array BioPharma Inc. (NASDAQ:ARRY) Recent Trading Information
Array BioPharma Inc. (NASDAQ:ARRY) closed its last trading session up +0.06 at 7.02 with 6,158,332 shares trading hands.
